ArticleHemaSphere2024

Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R-ISS II patients.

Maria Papatsirou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.